Healthcare professionals and patient groups have written to Vertex’s CEO Jeffrey Leiden in a bid to resolve a funding row over cystic fibrosis drugs, as UK MPs prepare to hold a public hear
Vertex has fired its chief operating officer and acting chief financial officer, Ian Smith, citing unspecified “personal behaviour” in breach of its code of conduct.
While UK cystic fibrosis patients continue their long wait for access to Vertex’s Orkambi, the drug has received a label extension from the European Commission allowing it to be used in you
Vertex is to file its two latest cystic fibrosis drugs with Scotland’s drug cost watchdog in a bid for NHS reimbursement – but an ongoing row over price in England is still unresolved.
UK politicians could go public with the price of Vertex's cystic fibrosis drug Orkambi, if the company does not strike a deal giving NHS patients access by the end of the month.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.